Diets and Cellular-Derived Microparticles: Weighing a Plausible Link With Cerebral Small Vessel Disease

Boehringer Taps Medidata E-clinical Tech For Another Five Years

Boehringer Ingelheim was an early adopter of Medidata's electronic data collection (EDC) platform for clinical trials, and has now extended and expanded the contract.

The new five-year alliance renews Boehringer's use of Medidata's Rave RDC toolkit, a cloud–based clinical data management system used to capture, manage, and report trial data, extending a collaboration that goes back more than seven years.

It also signs the German pharma company up for myMedidata, a suite of patient-facing technologies aimed at enhancing patient centricity and diversity in decentralised clinical trials (DCTs), currently seeing an upsurge in adoption by the pharma industry.

The web-based myMedidata patient portal provides access to electronic consent forms and electronic Clinical Outcome Assessment (eCOA) to capture patient experiences, as well as offering video-based investigator/patient visits.

Boehringer will also explore the use of Medidata's artificial intelligence-powered analytics tools to improve the "speed, success, and quality" of clinical trials, as well as its imaging capabilities.

"Boehringer Ingelheim and Medidata have a responsibility to innovate for the benefit of patients," said Anthony Costello, chief executive of Medidata's Patient Cloud unit.

"Together, we will be able to quickly improve access and diversity of participation in a wide range of clinical programmes," he added.

A recent IQVIA study suggested that DCTs – which allow data acquisition to be done remotely and directly from patients through digital devices like sensors, sponsor-provided devices, smartphones, and tablets – can provide significant reductions in key clinical trial challenges, including time to first patient in, overall recruiting time, protocol deviations, and screen failure rates.

Use of DCT approaches has rocketed since the start of the pandemic, but not without some concerns. For instance, there is a worry that DCT's reliance on digital technologies to allow remote access to clinical trials could compound disparities in access to clinical research among less tech-savvy demographics.

Medidata insists, however, that remote technologies "create opportunities to improve patient access, inclusion, and engagement across geographies, and improve patient diversity in clinical trials."

Earlier this month, Medidata launched a new Intelligent Trials Diversity module to help improve the equity of clinical trials by providing site-level participant demographic data, including race, sex, age, and ethnicity.

Medidata Launches Bundled Solutions To Support Oncology And Vaccine Trials, Accelerating Study Design And Execution

New offerings combine a variety of Medidata technologies and learnings from thousands of previous trials to streamline study management for Phase II and Phase III studies in specified therapeutic areas, reinforcing FDA guidance for patient-centered study design and execution

NEW YORK, October 31, 2024--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has introduced two new bundled offerings to meet the growing demands of oncology and vaccine research. Medidata Oncology Solutions and Medidata Vaccine Solutions reinforce the FDA guidance for patient-centered endpoints, adaptive trial designs, and trial diversity. By unifying key trial components such as real-time patient-reported outcomes and imaging management, these bundled solutions will aid sponsors by reducing trial complexity, accelerating decision-making, and improving assessments of treatment efficacy and safety.

"Oncology and vaccine trials face significant challenges in recruiting diverse patients, ensuring rapid execution, and maintaining and monitoring patient safety," said Joseph Schmidt, chief operating officer, Medidata. "By making these new bundled capabilities readily available to customers, we can deliver a solution built on Medidata's vast experience and expertise in these two important therapeutic areas. These bundles are designed to help customers navigate the complicated stages of these studies while advancing life-saving treatments."

Medidata, with more than 25 years of oncology and vaccine experience and the largest global trial datasets, has conducted approximately 9,000 oncology studies and 750 trials in vaccines. In 2023, it was recorded that 93% of oncology drug approvals went through Medidata. The company was also on the frontlines of COVID-19, supporting hundreds of trials, including the development of one of the most effective mRNA vaccines used to fight the virus.

Both solutions deliver a unified data ecosystem by integrating Medidata Rave EDC, Medidata eCOA, Medidata Rave Imaging, Medidata Clinical Data Studio, and Health Record Connect. For more information about Medidata's new oncology and vaccine solution bundles, visit our therapeutics landing page.

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 34,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,200 customers trust Medidata's seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.Medidata.Com and follow us @Medidata.

Story Continues

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.Com

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.

View source version on businesswire.Com: https://www.Businesswire.Com/news/home/20241031324962/en/

Contacts

Medidata PRMedidata.PR@3ds.Com

Analyst Relationsmedidata.AR@3ds.Com

Medidata Launches Bundled Solutions To Support Oncology And Vaccine Trials, Accelerating Study Design And Execution

Medidata Launches Bundled Solutions to Support Oncology and Vaccine Trials, Accelerating Study Design and ExecutionMedidata (BusinessWire India)2024-11-02 Business Wire India

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has introduced two new bundled offerings to meet the growing demands of oncology and vaccine research. Medidata Oncology Solutions and Medidata Vaccine Solutions reinforce the FDA guidance for patient-centered endpoints, adaptive trial designs, and trial diversity. By unifying key trial components such as real-time patient-reported outcomes and imaging management, these bundled solutions will aid sponsors by reducing trial complexity, accelerating decision-making, and improving assessments of treatment efficacy and safety.

 

"Oncology and vaccine trials face significant challenges in recruiting diverse patients, ensuring rapid execution, and maintaining and monitoring patient safety," said Joseph Schmidt, chief operating officer, Medidata. "By making these new bundled capabilities readily available to customers, we can deliver a solution built on Medidata's vast experience and expertise in these two important therapeutic areas. These bundles are designed to help customers navigate the complicated stages of these studies while advancing life-saving treatments."

 

Medidata, with more than 25 years of oncology and vaccine experience and the largest global trial datasets, has conducted approximately 9,000 oncology studies and 750 trials in vaccines. In 2023, it was recorded that 93% of oncology drug approvals went through Medidata. The company was also on the frontlines of COVID-19, supporting hundreds of trials, including the development of one of the most effective mRNA vaccines used to fight the virus.

 

Both solutions deliver a unified data ecosystem by integrating Medidata Rave EDC, Medidata eCOA, Medidata Rave Imaging, Medidata Clinical Data Studio, and Health Record Connect. For more information about Medidata's new oncology and vaccine solution bundles, visit our therapeutics landing page.

 

About Medidata

 

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 34,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,200 customers trust Medidata's seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.Medidata.Com and follow us @Medidata.

 

About Dassault Systèmes

 

Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.Com

 

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.

 

 

View source version on businesswire.Com: https://www.Businesswire.Com/news/home/20241031324962/en/

---